Sales reps sue over unpaid overtime

Share this article:
Thousands of pharmaceutical sales reps have filed a series of class action lawsuit claims against their former employers seeking tens of millions of dollars in back pay.

The claims were filed in New York, California, New Jersey and Connecticut on behalf of reps from across the country seeking overtime wages dating back two to six years, under federal and state statutes of limitations.

The companies affected are Pfizer, GlaxoSmithKline, Johnson & Johnson, AstraZeneca, Amgen, Eli Lilly, Hoffmann-La Roche, Bayer and Boehringer Ingelheim.

One former Lilly rep interviewed by the Associated Press said she quit after 18 years because her job encroached on weekends and vacations.

Another plaintiff, a 20-year Pfizer veteran, said the overtime requirements were “unfair” and that her boss said she “needed to be engaged in business 24/7.”

A Pfizer spokesman said in published reports the company would contest the lawsuit.

Under federal labor law, outside sales forces can be exempt from overtime pay. The plaintiffs argue that they don't qualify as sales reps because the doctors they visit aren't actually buying anything from them, said Charles Joseph, an attorney for the workers told The New York Times.  
Drug company executives denied the arguments in published reports. The overtime cases have all been moved to federal courts.  

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M Future Leaders


Register now

Early bird $1,950 before 31 October 2014

*Group discounts available on request 

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...